There may also be future potential for adjuvant miRNA-based therapies, as miR-7 has been shown to be an efficacious inhibitor of the EGFR signaling pathway in glioblastoma cell lines in vitro by direct inhibition of the EGFR receptor and further independent down-regulation of AKT, leading to a decrease in cell invasiveness (77). The gene discussed is EGFR; the disease is glioblastoma.